

SESSIONS

DAY 1 - JANUARY 10

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

BiotechBikers Virtual Zwift and Peloton Ride and Networking

06:30 - 07:30

Networking

Get energized and connect with other #BiotechBikers

We will hold 30-minute virtual bike rides on Peloton and Zwift, immediately followed by 30 minutes of networking on Zoom. Feel free to just join the networking session if you can't make the ride.

Register for the ride here:

<https://get.informaconnect.com/ebd/biotech-showcase-bike-ride/>

About [BiotechBikers](#)

BiotechBikers brings together "bike-minded" biopharma and life science professionals in a unique networking community based around group rides, meetups and other social events. Visit our website for more information and join our LinkedIn community to hear about upcoming rides and activities.

Outsmarting Cancer: Next Generation Therapies

08:00 - 09:00

Biotech Showcase 1

The past decades have brought us new oncology therapies including mAbs, vaccines, checkpoint inhibitors and there is still more on the horizon. Emerging directions include compounds that inhibit both CDK2 and CDK9, activate the immune system, among others as well as precision therapies. This discussion will focus on emerging and evolving directions in the development of novel therapeutics for difficult to treat cancers.

Participants

Moderator: Kevin DeGeeter - Managing Director, Healthcare Research, Oppenheimer & Co. Inc.

Panelist: William Ho - CEO, In8bio

Panelist: Kanya Rajangam - CMO, Nkarta Therapeutics

Panelist: Spiro Rombotis - President and CEO, Cyclacel Pharmaceuticals

Panelist: Weimin Tang - CBO, I-Mab Biopharma

Panelist: Lihua Zheng - CBO and Co-Founder, AnHeart Therapeutics

Psychedelics: Once Stigmatized, Are Now the Newest Therapeutics on the Block for Mental Health

08:00 - 09:00

Biotech Showcase 2

Finally, new therapeutic options are emerging for mental health diseases including depression, anxiety, pain, addiction, PTSD, and other behavioral health disorders which have long been considered intractable and untreatable. Psychedelics are going mainstream and are poised to create a revolution in mental health. Psychedelics have demonstrated their clinical efficacy in treating disorders that affect thousands of people. But while psychedelics are stepping into the limelight, there are still a number of hurdles to overcome including intellectual property protection and FDA/ EMEA approval pathways.

Participants

Moderator: Walter Greenleaf - Distinguished Visiting Scholar, Stanford University's MediaX Program

Panelist: Bob Dougherty - VP, Digital Health Research, COMPASS Pathways

Panelist: Doug Drysdale - CEO, Cybin

Panelist: Adam Gazzaley - David Dolby Distinguished Professor of Neurology, Physiology & Psychiatry, UC San Francisco

Panelist: Berra Yazar-Klosinski - CSO, Multidisciplinary Association for Psychedelic Studies (MAPS)

Company presentations will be held On-Demand for viewing in the partneringONE system.

On demand
Company Presentations

ARM Cell and Gene State of the Industry Briefing: Introduction & Industry Update

08:00 - 08:20

Additional Programming: Cell and Gene Therapies State of the Industry Briefing

This Briefing will be held virtually via Zoom. Please register [here](#) for the Briefing on January 10, after which you will receive a Zoom link.

Participants

Speaker: Janet Lambert - CEO, Alliance for Regenerative Medicine

Speaker: Emile Nuwaysir - CEO, Ensoma; Chairman, Alliance for Regenerative Medicine (ARM); Chairman, CEO, BlueRock Therapeutics

2022: A Banner Year for Rare Genetic Disease Therapies?

08:20 - 09:05

Additional Programming: Cell and Gene Therapies State of the Industry Briefing

This Briefing will be held virtually via Zoom. Please register [here](#) for the Briefing on January 10, after which you will receive a Zoom link.

Participants

Moderator: Bob Smith - SVP, Global Gene Therapy Business, Pfizer Inc.

Panelist: Harold Bernstein - Chief Medical Officer and SVP, BioMarin

Panelist: Jason Cole - CBO, bluebird bio

Panelist: Bobby Gaspar - CEO, Orchard Therapeutics

Panelist: Suma Krishnan - Founder and COO, Krystal Biotech

The Decision to Launch on your Own: Critical Success Factors

09:00 - 10:00

Biotech Showcase 1

Companies are increasingly retaining control over the development of their innovations and deciding to commercialize on their own. Our panel will share perspectives on what is contributing to this trend and how innovative models are changing the commercial playbook.

Participants

Moderator: Todd Matthews - Senior Director, Corporate Alliances, IQVIA

Panelist: Christoph Broja - Principal, Gurnet Point Capital

Panelist: Susan Kitlas - VP, Precommercial Segment Lead, IQVIA

Panelist: Francesco Lavino - CEO, F2G

Next Generation Therapies to Fight Cancer

09:05 - 09:50

Additional Programming: Cell and Gene Therapies State of the Industry Briefing

This Briefing will be held virtually via Zoom. Please register [here](#) for the Briefing on January 10, after which you will receive a Zoom link.

Participants

Moderator: Robert Ang - CEO, Vor Biopharma

Panelist: Osvaldo Flores - CEO, Century Therapeutics

Panelist: Steven Kelly - President and CEO, CARISMA Therapeutics

Panelist: Alison Moore - Chief Technical Officer, Allogene Therapeutics

SESSIONS

DAY 1 - JANUARY 10

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

Royalty Licenses: An Economic Asset Often Ignored

10:30 - 11:00
Biotech Showcase 1

Signing a licensing agreement with a Big Pharma is a key validation moment for every R&D-stage biotech company. In addition to validation, upfront and milestone payments provide capital for R&D efforts.

However, as the asset moves into the clinic, a company can wait until it enters Phase 3 for another infusion of capital. How many contracts with Big Pharma are you holding that are in Phase 1 or Phase 2 and what value are you getting for them? Royalty monetization is a mechanism that could provide a non-dilutive financing alternative. Realizing value from a royalty license is a valuable tool that should be in every CEO and CFO's toolbox.

Participants

Panelist: Tom Burns - Senior VP, Finance and CFO, XOMA

Panelist: James R. Neal - CEO and Member, Board of Directors, XOMA

Panelist: Juliane Snowden - Founder, The Oratorium Group

Beyond the COVID-19 Crisis: What We Learned in Record Time and How it Will Advance the Future

12:00 - 13:00
Biotech Showcase 1

While there is no silver lining to a global pandemic that claimed millions of lives and disrupted every aspect of society, the response to COVID-19 has yielded remarkable progress and innovation in many areas that should be here to stay. Among them, telemedicine, intensified work on wearable and home-based technologies, the safe and effective use of data derived from these and other sources, and a new look at our critical supply chain. Leaders in the field of biotechnology, pandemic prevention and response, and innovative clinical delivery will share perspectives on what should be adopted to ensure effective control of COVID-19 and to enhance healthcare.

Participants

Moderator: Jeremy Abbate - Publisher, Scientific American

Panelist: Mara Aspinall - Managing Director, Health Catalysts Group

Panelist: Rick Bright - CEO, Pandemic Prevention Institute & Senior VP, Pandemic Prevention & Response, Health Initiative, The Rockefeller Foundation

Panelist: Michael Brooks - Chief Development Officer and Global Head, Clinical Development Solutions, Syneos Health

Panelist: Michelle McMurry-Heath - President and CEO, Biotechnology Innovation Organization (BIO)

Investment Trends in Digital Medicine

14:45 - 15:45
Digital Medicine and Medtech Showcase

Imperial Ballroom

Participants

Moderator: Katya Hancock - Investment Network Director, StartUp Health

Panelist: David J. Kim - Managing Director, DigiTx Partners

Panelist: Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital

Panelist: Liz Rockett - Managing Director, Kaiser Permanente Ventures

Investing for Commercial Success as an Emerging Company

16:00 - 17:00
Biotech Showcase 1

Launching a new drug is complex. And too often, launches fail to meet expectations.

Whether or not the plan is to partner, out-license or go it alone, executives at emerging companies need to understand what levels of spend are appropriate to prepare a product for a successful launch. Many clinical-stage companies find themselves either underfunding and subsequently underperforming in the market, or overfunding and incurring costs that do not add incremental value to commercial success. A strategic analysis of influential factors can help these companies determine whether to spend more or less, earlier or later in the process as they bring their product to market.

This session takes a deeper dive into the factors that influence commercial spend decisions and strategies for mitigating risk – and how those decisions in turn influence commercial success.

Participants

Speaker: Naveen Murthy - Senior Managing Director, Head of Product & Franchise Strategy, Commercial Advisory Group, Consulting, Syneos Health

Speaker: Sachin Purwar - Director of Commercial Advisory Group, Consulting, Syneos Health

Speaker: Michael Sarshad - Director of Commercial Advisory Group, Consulting, Syneos Health

Pharma Perspective: A Post-Pandemic Time of Transformation

16:30 - 17:30
Biotech Showcase 2

COVID-19 has been a catalyst for a tremendous amount of change across the pharmaceutical and biotech industries. It acted as an accelerant for progress in its use of new digital technologies, advances at regulatory agencies, and it certainly seemed to accelerate the flow of capital into the biotech space. What is here to stay?

Participants

Moderator: Bryan Katz - Senior VP and Global Head, Solution Development, Syneos Health

Panelist: Phyllis Barkman Ferrell - Global Head, External Engagement, Alzheimer's disease and Neurodegeneration, Eli Lilly & Company

Panelist: Chihiro Hosoya - Head of Venture Management and Business Development, Astellas Rx+ Business Accelerator

Panelist: Philippe Lopes-Fernandes - Executive VP and CBO, Ipsen

Panelist: John McDonald - Corporate VP, Global R&D Business Development, Novo Nordisk

SCHEDULE

DAY 1 - JANUARY 10 -

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

TIME	ADDITIONAL PROGRAMMING: CELL AND GENE THERAPIES STATE OF THE INDUSTRY BRIEF- ING	BIOTECH SHOWCASE 1	BIOTECH SHOWCASE 2	COMPANY PRESENTATIONS	DIGITAL MEDICINE AND MEDTECH SHOWCASE	NETWORKING
06:00						06:30 - BiotechBikers Virtual Zwift and Peloton Ride and Networking
07:00						
08:00	08:00 - ARM Cell and Gene State of the Industry Briefing: Introduction & Industry Update 08:20 - 2022: A Banner Year for Rare Genetic Disease Therapies?	08:00 - Outsmarting Cancer: Next Generation Therapies	08:00 - Psychedelics: Once Stigmatized, Are Now the Newest Therapeutics on the Block for Mental Health	On demand - Company presentations will be held On-Demand for viewing in the partneringONE system.		
09:00	09:05 - Next Generation Therapies to Fight Cancer	09:00 - The Decision to Launch on your Own: Critical Success Factors				
10:00		10:30 - Royalty Licenses: An Economic Asset Often Ignored				
11:00						
12:00		12:00 - Beyond the COVID-19 Crisis: What We Learned in Record Time and How it Will Advance the Future				
13:00						

SCHEDULE

DAY 1 - JANUARY 10 -

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

TIME	ADDITIONAL PROGRAMMING: CELL AND GENE THERAPIES STATE OF THE INDUSTRY BRIEF- ING	BIOTECH SHOWCASE 1	BIOTECH SHOWCASE 2	COMPANY PRESENTATIONS	DIGITAL MEDICINE AND MEDTECH SHOWCASE	NETWORKING
14:00					14:45 - Investment Trends in Digital Medicine	
15:00						
16:00		16:00 - Investing for Commer- cial Success as an Emerging Company	16:30 - Pharma Perspective: A Post-Pandemic Time of Trans- formation			

SESSIONS

DAY 2 - JANUARY 11

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

Cardiometabolic Syndrome: The Largest Global Threat to Mortality

08:00 - 09:00
Biotech Showcase 1

Cardiometabolic syndrome, a constellation of chronic diseases affecting an ageing population, is on the rise globally. Its societal burden, a mix of chronic and non-communicable diseases, is staggering and growing. New therapeutics are emerging today that can slow down, push back, and even prevent disease.

Participants

Moderator: Gautam Aggarwal - Partner, Triangle Insights Group, LLC

Panelist: Karin Conde-Knape - Senior VP Global Drug Discovery, Novo Nordisk

Panelist: Crystal Nyitray - CEO, Encellin

Panelist: Komathi Stem - COO, Glooko

Aduhelm: Stimulating the Next Generation of AD Treatment

08:00 - 09:00
Biotech Showcase 2

Alzheimer's disease is ruthless. Out of the hundreds of candidates advanced to treat the disease, up until a few months ago there had only been five drugs approved, and none of them significantly stopped or slowed the damage. The momentum of the AD space changed in June of 2021 with the FDA's approval of the first potentially disease modifying drug, Biogen's Aduhelm. While Aduhelm's approval was controversial, it has stimulated investment in the space that may lead to the next generation of drugs. In this panel we will discuss the shift in AD investment sentiment and some of the new avenues these innovative companies are pursuing.

Participants

Moderator: John Vandermosten - Senior Biotechnology Analyst, Zacks Investment Research

Panelist: Phyllis Barkman Ferrell - Global Head, External Engagement, Alzheimer's disease and Neurodegeneration, Eli Lilly & Company

Panelist: Travis Bond - CEO, Altoida, Inc.

Panelist: Michael McFadden - CEO, Alpha Cognition, Inc.

Panelist: Lisa Ricciardi - CEO, Cognition Therapeutics, Inc.

Panelist: Brent Vaughan - CEO, Cognito Therapeutics

Panelist: Eugene Williams - Chairman and CEO, ProMIS Neurosciences

Dealmakers' Intentions: The Year Ahead

08:00 - 09:00
Biotech Showcase 3

Pandemic uncertainty sent biopharmaceutical dealmaking into a tailspin in 2020 and the drop-off continued through 2021. But it would be a mistake to assume that COVID-19 has forever changed the dynamics of dealmaking. While months of lockdowns, work disruptions and economic uncertainty have had an impact, important trends that began before COVID-19 will contribute to the backdrop for buying and selling. So, what's in store for our industry in 2022?

This session will reveal the results of the Syneos Health Dealmakers' Intentions Study, a forward-looking measure of dealmaking activity in the biopharmaceutical industry. Now in its 12th year, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for dealmaking over the next year or more.

Participants

Speaker: Sachin Purwar - Director of Commercial Advisory Group, Consulting, Syneos Health

Company presentations will be held On-Demand for viewing in the partneringONE system.

On demand
Company Presentations

Reimagining Clinical Trials through Decentralization

10:00 - 11:00
Digital Medicine and Medtech Showcase

In the clinical trials realm, the application of decentralized capabilities—from sensors and wearables to mobile nurses—reimagines a process that was ripe for an overhaul. This session explores how leveraging technologies and personalized communications that more closely mirror what patients are accustomed to can lead to better clinical trials and outcomes. Panelists will review how decentralized trials create ways to better the standard of care, accelerate patient access, improve retention, and increase diversity, while providing the potential to increase efficiency and data capture.

Participants

Moderator: Maria Fotiu - Executive VP of Decentralized Solutions, Syneos Health

Panelist: Keith Fern - VP, Strategic Partnerships, Elligo Health Research

Panelist: Alison Holland - Head of Decentralized and Remote Trials, Medable

Panelist: Juliet Hulse - Senior Director, Global RN Strategy and Patient Advocacy, Illingworth Research Group™, a Syneos Health Company, USA

The Biden Policy: Will its Impact on the Biopharma Sector be a Net Gain or Loss?

12:00 - 13:00
Biotech Showcase 1

It's no secret that the biopharma industry is facing headwinds, in particular with regard to drug pricing. But, will Build Back Better be all bad? Perhaps not.

Participants

Moderator: Simone Fishburn - VP and Editor in Chief, BioCentury

Panelist: Alice Valder Curran - Partner, Hogan Lovells

Panelist: Paul J. Hastings - President and CEO, Nkarta Therapeutics, Inc.

Panelist: Myrtle Potter - CEO, Sumitovant

Panelist: Peter Rubin - Executive Director, No Patient Left Behind

Sepsis in the Era of COVID-19: Understanding Compounding Risk Factors for Infection and Outcomes

16:30 - 17:30
Biotech Showcase 1

Sepsis, the leading cause of death in hospitals, takes the lives of 270,000 people in the US alone. With the advent of SARS CoV-19 diagnosis and treatment of sepsis is more challenging because inflammatory responses to COVID as well as to bacterial, fungal, and other viral pathogens are similar and may comprise early diagnosis when every minute counts.

Participants

Moderator: Thomas J. Walsh - Director, Institute for Innovative Therapeutics and Diagnostics; Henry Schueler Foundation Scholar in Mucormycosis; Investigator, Emerging Infectious Diseases, Save Our Sick Kids

Panelist: Aparna Ahuja - CMO, T2 Biosystems

Panelist: Rick Bright - CEO, Pandemic Prevention Institute & Senior VP, Pandemic Prevention & Response, Health Initiative, The Rockefeller Foundation

Panelist: Matt McCarthy - Hospitalist, Weill Cornell Medical Center; Associate Attending Physician, New York-Presbyterian Hospital; Associate Professor of Medicine, Weill Cornell Medical College, Cornell University

Panelist: Steven Q. Simpson - Professor of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Kansas, and 83rd President of the American College of Chest Physicians, ,

SCHEDULE

DAY 2 - JANUARY 11 -

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

TIME	BIOTECH SHOWCASE 1	BIOTECH SHOWCASE 2	BIOTECH SHOWCASE 3	COMPANY PRESENTATIONS	DIGITAL MEDICINE AND MEDTECH SHOWCASE
08:00	08:00 - Cardiometabolic Syndrome: The Largest Global Threat to Mortality	08:00 - Aduhelm: Stimulating the Next Generation of AD Treatment	08:00 - Dealmakers' Intentions: The Year Ahead	On demand - Company presentations will be held On-Demand for viewing in the partneringONE system.	
09:00					
10:00					10:00 - Reimagining Clinical Trials through Decentralization
11:00					
12:00	12:00 - The Biden Policy: Will its Impact on the Biopharma Sector be a Net Gain or Loss?				
13:00					
14:00					
15:00					
16:00	16:30 - Sepsis in the Era of COVID-19: Understanding Compounding Risk Factors for Infection and Outcomes				

SESSIONS

DAY 3 - JANUARY 12

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

Women's Health: Progress and Innovation Continue to Drive Increased Investor Interest

08:00 - 09:00
Biotech Showcase 1

2020 was the tipping point. The number of investments into the women-focused digital health and therapeutic space grew by 105% according to Rock Health just last year. Women make up 51% of the population and this new attention and investment is finally addressing women's health issues that have traditionally been dismissed, underfunded, and ignored. A group of CEOs, supported by investors, is changing the tide

Participants

Moderator: Jennifer Friel Goldstein - Managing Partner, Life Science and Healthcare, SVB Capital

Panelist: Jill Angelo - CEO, Gennev

Panelist: Martin Lehr - CEO and Director, Context Therapeutics

Panelist: Tanya Petrossian - CEO, EndoCyclic Therapeutics

Panelist: Mylene Yao - CEO, Univfy

Panelist: Maryam Ziaei-Moayyed - CEO, iSono Health

Rare Disease: The Value Proposition Keeps Expanding

08:00 - 09:00
Biotech Showcase 2

Rare disease drug developers maintained a steady lead in their financing and dealmaking, with dealmaking heating up as big pharma and big biotech snapped up companies. Innovative approval pathways for rare and ultra-rare diseases are making investment in this space more approachable and more interesting for larger patient populations. With a steady beat of success, private and public capital continues to flow into the space. Let's discuss the future.

Participants

Moderator: Mani Foroohar - Managing Director, Senior Research Analyst, Leerink Partners

Panelist: Beth Hoffman - Founder and CEO, Origami Therapeutics, Inc.

Panelist: Rachelle Jacques - CEO, Enzyvant

Panelist: Jeremy Levin - CEO and Board of Directors Chair, Ovid Therapeutics, BIO

Evolving Role of Digital Therapeutics

08:00 - 09:00
Digital Medicine and Medtech Showcase

This panel will explore the current market space for digital therapeutics, including the evidence and benefits of the products, their place in treating disease, and challenges patients face in accessing therapies. It will identify challenges and payer needs related to the evidence required to ensure coverage of digital therapeutics. It will discuss the importance of regulatory guidance in defining and categorizing digital therapeutics and identify opportunities to highlight the expertise of the stakeholders in determining the value of digital therapeutics in health care.

Participants

Moderator: Susan Cantrell - CEO, Academy of Managed Care Pharmacy (AMCP)

Panelist: Everett Crosland - CCO, Cognito Therapeutics

Panelist: Yuri Maricich - CMO and Head of Development, Pear Therapeutics

Panelist: Robert O'Brien - VP, Real Endpoints

Panelist: Beth Rogozinski - CEO, Oncoustics

Company presentations will be held On-Demand for viewing in the partneringONE system.

On demand
Company Presentations

Early Seed Financing: What are the Best Funding Strategies for Biotech Start-ups?

10:00 - 11:00
Seed Showcase

For emerging biotech start-up companies, finding funding is one of the earliest challenges they will face. They'll be heavy with expenses, even if the founders don't take a salary. Funding a biotech start-up is no easy task, and can influence the long-term success of a company. Learning from downfalls is valuable in any pursuit, and biotech funding strategies are no exception.

Participants

Moderator: Ben Johnson - Head of Early Stage Life Science, Silicon Valley Bank

Panelist: Jim Anthony - EVP and Global Head, Parexel Biotech

Panelist: Michael Davitian - VP, Health Advances

Panelist: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist, R&D Global Search & Evaluation, Novo Nordisk

Panelist: Marian Nakada - VP, Venture Investments, Johnson & Johnson Innovation, JJDC

Panelist: Andrew Strong - Partner, Hogan Lovells

Finance: The 2022 Outlook

12:00 - 13:00
Biotech Showcase 1

In a year in which biotech delivered therapies for Covid, funding was at an all-time record in the industry, while markets took a nose-dive. Will the markets rebound and funding be abundant in 2022?

Participants

Moderator: Dennis J. Purcell - Founder and Senior Advisor, Aisling Capital

Panelist: Gabriel P. Cavazos - Senior Managing Director, Investment Banking, SVB Leerink

Panelist: Tim Opler - Partner & Co-Founder, Torrey

Panelist: Liz Rockett - Managing Director, Kaiser Permanente Ventures

Panelist: Camille Samuels - Partner, Venrock

COVID: What to Expect Next

14:00 - 14:20
Biotech Showcase 1

Participants

Interviewer: Andrew Meadow - General Partner, Health Innovation Capital

Interviewee: Steve Brozak - President, WBB Securities LLC

Pharma's Digital Future

15:30 - 16:30
Digital Medicine and Medtech Showcase

Pharma companies have recognised the importance of digital platforms and approaches in discovery, therapeutics, data use and management and other areas, signaled by new acquisitions and partnerships and the creation of dedicated departments. What will be the focal points for pharma's digital engagement going forward? What are some of the strategies being adopted to integrate and develop these approaches going forward? Where will the impact of AI/ML or Big Data be felt the most?

Participants

Moderator: Matt Miller - CEO, StudyKIK

Panelist: Chihiro Hosoya - Head of Venture Management and Business Development, Astellas Rx+ Business Accelerator

Panelist: Michelle Longmire - CEO and Co-Founder, Medable

Panelist: Owen McCarthy - President and Founder, MedRhythms

SESSIONS

DAY 3 - JANUARY 12

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

Media Round-Up: Heard Around the Square

16:30 - 17:30
Biotech Showcase 1

After 20 months of uncertainty and a cautious return to normal, journalists will discuss what was “heard around the virtual square” as the most important week of the biotech calendar draws to a close.

Participants

Moderator: Erik Clausen - Managing Partner, CG Life

Panelist: Querida Anderson - Managing Editor, FierceBiotech, Healthcare, Medtech & Pharma

Panelist: Andy Dunn - Senior Biopharma Reporter, Business Insider

Panelist: Michael Fitzhugh - Managing Editor, BioWorld

Panelist: Mandy Jackson - Managing Editor, US Commercial News, Scrip/The Pink Sheet

Panelist: Ron Leuty - Biotech Reporter, San Francisco Business Journal

SCHEDULE

DAY 3 - JANUARY 12 -

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

TIME	BIOTECH SHOWCASE 1	BIOTECH SHOWCASE 2	COMPANY PRESENTATIONS	DIGITAL MEDICINE AND MEDTECH SHOWCASE	SEED SHOWCASE
08:00	08:00 - Women's Health: Progress and Innovation Continue to Drive Increased Investor Interest	08:00 - Rare Disease: The Value Proposition Keeps Expanding	On demand - Company presentations will be held On-Demand for viewing in the partneringONE system.	08:00 - Evolving Role of Digital Therapeutics	
09:00					
10:00					10:00 - Early Seed Financing: What are the Best Funding Strategies for Biotech Start-ups?
11:00					
12:00	12:00 - Finance: The 2022 Outlook				
13:00					
14:00	14:00 - COVID: What to Expect Next				
15:00				15:30 - Pharma's Digital Future	
16:00	16:30 - Media Round-Up: Heard Around the Square				

Clinical Research: A Driver of Success for the Biotech Industry and What's Ahead

On demand
Biotech Showcase

The COVID-19 pandemic shined a spotlight on the importance of clinical research to the success of the biotech industry's drive to bring new therapies to market safely and efficiently. In this fireside chat, industry veteran and STAT reporter, Ed Silverman, and Parexel CEO, Jamie Macdonald, will discuss the legacy of CROs, how the pandemic accelerated and changed the industry, and emerging industry trends driving growth in 2022, including the phenomenal investment in biotech and the booming pipeline. The COVID-19 pandemic shined a spotlight on the importance of clinical research to the success of the biotech industry's drive to bring new therapies to market safely and efficiently. In this fireside chat, industry veteran and STAT reporter, Ed Silverman, and Parexel CEO, Jamie Macdonald, will discuss the legacy of CROs, how the pandemic accelerated and changed the industry, and emerging industry trends driving growth in 2022, including the phenomenal investment in biotech and the booming pipeline.

Participants

Interviewer: Ed Silverman - Senior Writer and Pharamlot Columnist, STAT

Interviewee: Jamie Macdonald - CEO, Parexel

In Conversation with the FDA's Bakul Patel

On demand
Digital Medicine and Medtech Showcase

Participants

Moderator: Wade Ackerman - Partner, Covington & Burling LLP

Speaker: Bakul Patel - Director of Digital Health Center of Excellence, Food and Drug Administration

Keynote: The state of China life science

On demand
China Showcase

Participants

Speaker: Greg Scott - Founder and Chairman, ChinaBio® Group

Company presentations will be held On-Demand for viewing in the partneringONE system.

On demand
Company Presentations

Regulatory Update for AI Enabled Hardware

On demand
Digital Medicine and Medtech Showcase

Participants

Moderator: Lina Kontos - Partner, Hogan Lovells

Panelist: Esther Bleicher - Chief Counsel, Therapeutics and Product & Technology, Valo Health

Panelist: Jennifer Newberger - VP Head of Regulatory Affairs and Compliance, Cognito Therapeutics

Panelist: Valentin Tablan - Chief AI Officer, Ieso Digital Health

Dendreon: Pioneering the path for cellular therapies and forging the path to the future

On demand
Biotech Showcase

Since 1992, Dendreon has pioneered an innovative way to target cancer by harnessing the body's own immune system. Listen to how Dendreon navigated the challenges of being the first company to develop autologous cell therapy, what they learned, and how they are leveraging that resilience and expertise to continue to forge the future of cell therapies (through partnerships with other companies).

Participants

Interviewer: Ben Bonifant - Partner, Triangle Insights

Interviewee: Nadeem Sheikh - VP, Research and Manufacturing Sciences, Dendreon

It's a small world after all: the impact of global economies and global health needs to the biotech sector in China

On demand
China Showcase

Investments and deals continue to increase in China as we see more innovative products developing and biotech companies emerging. Despite travel restrictions and other obstacles caused by the pandemic, there is a growing appetite for deals. Investors share their insights on areas of growth and expectations for the year ahead.

Participants

Moderator: Greg Scott - Founder and Chairman, ChinaBio® Group

Panelist: Yuwen Liu - Founding Partner and Founder, BOHE Angel Fund, Bio2

Panelist: Elizabeth Kelly - Fund Manager, Asia Innovation Ventures

Panelist: Victor E. Tong - Partner, Decheng Capital

Environmental Surveillance and the Future of Pandemic Prevention

On demand
Biotech Showcase

The recent emergence of the Omicron variant has yet again demonstrated the world's vulnerability to an emergent threat. Modern day surveillance systems are highly reactive; by the time a health system or lab detects and reports a variant of concern, it is already too late to contain its spread. Wastewater testing is a cost-effective, anonymous tool that can complement existing surveillance methods and reach populations traditionally left out of disease monitoring. In this panel, we will hear from industry leaders who are advancing the field of environmental testing, transforming pandemic prevention into a more equitable and proactive practice.

Participants

Moderator: Helen Stembridge - UKHSA Strategic Engagement and Director of Projects, WholeShip Consulting Ltd

Panelist: Mariana Matus - CEO and Co-Founder, Biobot Analytics

Panelist: Catherine Phillips - Innovation Architect, Heathrow Airport

Panelist: Sam Scarpino - Managing Director, Pathogen Surveillance, Pandemic Prevention Institute

The next wave of innovative companies driving global partnerships

On demand
China Showcase

Innovative companies developing new therapeutics, platform technologies and AI & digital health tools share their strategies in expanding their innovations through international partnerships and novel business models

Participants

Moderator: Debra Yu - President and CSO, LianBio

Panelist: Michelle Chen - CBO, Insilico Medicine

Panelist: Miranda Gottlieb - Venture Partner, Pappas Capital

Panelist: Alan Jiang - CSO, XtalPi Inc.

SESSIONS

ON DEMAND SESSIONS

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

The Road to an RMAT (Regenerative Medicine Advanced Therapy) FDA Approval

On demand
Biotech Showcase

The recent FDA approval of RETHYMIC (allogeneic processed thymus tissue-agdc) was a milestone in the biotech sector as one of the first three Regenerative Medicine Advanced Therapy (RMAT)-designated products to be approved since the program was implemented, and the first tissue-based regenerative therapy. From early interactions with the agency, to a CMC-focused Complete Response Letter, to CRL resolution, Enzyvant regulatory and CMC team members share their insights about the twists and turns on the path to a successful RMAT FDA approval.

Participants

Moderator: Ted Haack - VP, Lattice Point Consulting

Panelist: Kevin Healy - Senior VP, Regulatory Affairs, Pharmacovigilance, and Quality, Enzyvant

Panelist: Karen Pihel - Senior Director, CMC Regulatory Affairs, Enzyvant

Panelist: Larry Weiner - VP of Pharmaceutical Development & Manufacturing, Enzyvant

SCHEDULE

ON DEMAND SESSIONS -

Biotech Showcase

Join us virtually
January 10–12, 2022 &
January 17–19, 2022

TIME	BIOTECH SHOWCASE	CHINA SHOWCASE	COMPANY PRESENTATIONS	DIGITAL MEDICINE AND MEDTECH SHOWCASE
08:00	On demand - Clinical Research: A Driver of Success for the Biotech Industry and What's Ahead	On demand - Keynote: The state of China life science	On demand - Company presentations will be held On-Demand for viewing in the partner-ingONE system.	On demand - In Conversation with the FDA's Bakul Patel
09:00	On demand - Dendreon: Pioneering the path for cellular therapies and forging the path to the future	On demand - It's a small world after all: the impact of global economies and global health needs to the biotech sector in China		On demand - Regulatory Update for AI Enabled Hardware
10:00	On demand - Environmental Surveillance and the Future of Pandemic Prevention	On demand - The next wave of innovative companies driving global partnerships		
11:00	On demand - The Road to an RMAT (Regenerative Medicine Advanced Therapy) FDA Approval			